141196-64-7

Basic information

• Product Name: DL-2-(2-Chlorophenyl)glycine
• Synonyms: DL-2-(2-Chlorophenyl;DL-Chlorophenylglycine;DL- ortho glycine;Benzeneacetic acid, .alpha.-amino-2-chloro-;H-DL-Phg(2-Cl)-OH;RARECHEM AK ML 0504;O-CHLORO-A-AMINOPHENYLACETIC ACID;2-CHLORO-DL-PHENYLGLYCINE
• CAS NO: 141196-64-7
• Molecular Formula: C₈H₈ClNO₂
• Molecular Weight: 185.61
• EINECS: 1592732-453-0
• Product Categories: Pharmaceutical Intermediates
• Mol File: 141196-64-7.mol

Chemical Properties

• Boiling Point: 318.8 °C at 760 mmHg
• Flash Point: 146.6 °C
• Appearance: /
• Density: 1.392 g/cm³
• Vapor Pressure: 0.000148mmHg at 25°C
• Refractive Index: 1.603
• CAS DataBase Reference: DL-2-(2-Chlorophenyl)glycine(CAS DataBase Reference)
• NIST Chemistry Reference: DL-2-(2-Chlorophenyl)glycine(141196-64-7)
• EPA Substance Registry System: DL-2-(2-Chlorophenyl)glycine(141196-64-7)

Safety Data

• Hazard Codes: Xi
• Statements: 36/37/38
• Safety Statements: 26
• WGK Germany: 3
• F: 10-23
• Hazardous Substances Data: 141196-64-7(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
DL-2-(2-Chlorophenyl)glycine is used as a key intermediate in the synthesis of antithrombotic drugs, specifically flupidogrel. Its unique structure allows for the development of medications that can effectively prevent blood clot formation, which is crucial in the treatment and management of conditions such as stroke, heart attack, and deep vein thrombosis.
The application of DL-2-(2-Chlorophenyl)glycine in the pharmaceutical industry is primarily due to its ability to serve as a building block for the creation of antithrombotic drugs. Its chemical properties enable the formation of specific drug molecules that can target and inhibit the processes involved in blood clotting, thus providing a valuable treatment option for patients at risk of thrombotic events.

InChI:InChI=1/C8H8ClNO2/c9-6-4-2-1-3-5(6)7(10)8(11)12/h1-4,7H,10H2,(H,11,12)

Upstream product

• 144616-14-8 ortho-chlorophenylmalonic acid 
• 103029-09-0 5-(2-chlorophenyl)imidazolidine-2,4-dione 
• 143-33-9 sodium cyanide 
• 89-98-5 2-chloro-benzaldehyde 
• 187243-26-1 N-(o-chlorophenyl)hydantoin 
• 13312-84-0 2-chloromandelonitrile 

Downstream Products

• 111-85-3 n-chlorooctane 
• 131402-95-4 Amino-(2-chloro-phenyl)-acetic acid octyl ester; hydrochloride 
• 808732-87-8 α-(2-thiophenylethylamino)-o-chlorophenylacetic acid 
• 141315-51-7 S(+)-chlorophenylglycine-d-camphoric sulfonic acid 
• 141109-14-0 2-(2-chlorophenyl)glycine methyl ester hydrochloride 
• 29270-30-2 α-bromo-2-chlorophenyl acetic acid 
• 313490-25-4 [(tert-butoxycarbonyl)amino](2-chlorophenyl)acetic acid 
• 127428-62-0 2-amino-2-(2-chlorophenyl)ethan-1-ol 
• 1276118-73-0 C₁₁H₁₃ClN₂O 
• 1276118-74-1 C₁₂H₁₅ClN₂O 
• 1276118-75-2 C₁₃H₁₇ClN₂O 
• 1276118-81-0 C₁₆H₁₄ClNO₂ 
• 1313411-65-2 C₁₉H₁₇ClN₂O₂ 
• 1276118-82-1 C₁₂H₁₃ClN₂O₂ 

Relevant articles and documents

Method for continuously and quickly preparing DL-phenylglycine and analogue thereof

The invention provides a method for continuously and quickly preparing DL-phenylglycine and an analogue thereof. The method comprises the steps of adding 2-hydroxyl-phenylacetonitrile and an analoguethereof (cyanohydrin for short) and an aqueous ammonium bicarbonate solution into a microchannel reactor for a reaction, controlling the reaction temperature to be 80-130 DEG C, and controlling the reaction pressure to be 0.5-2.0 MPa, wherein the standing time of the reactants in a microchannel is 1-8 min, and an aqueous solution of 5-phenyl-hydantoin and an analogue thereof (hydantoin for short)is obtained; adding the hydantoin and alkali into the microchannel reactor for a reaction, controlling the reaction temperature to be 120-200 DEG C, and controlling the reaction pressure to be 1.0-3.5MPa, wherein the standing time of the reactants in the microchannel is 1-8 min, and then a saline solution of phenylglycine and an analogue thereof is obtained; conducting acidification neutralization and crystallization to obtain the phenylglycine and the analogue thereof. According to the method, the microchannel reactor is adopted, the reaction time is greatly shorted, the reaction speed is increased, pyrolysis and polymerization of the cyanohydrin are reduced, no by-products are generated, the products are high in yield, clean and environmentally friendly, and the production cost is lowered.

Preparation method for D, L-phenylglycine and analogue thereof

The invention provides a preparation method for D, L-phenylglycine and an analogue thereof. According to the method, benzaldehyde, an analogue thereof and hydrocyanic acid are adopted as raw materials and subjected to cyanidation reaction, and then 2-hydroxy-benzyl cyanide or 2-hydroxy-benzyl cyanide analogue (cyanohydrin for short) is generated. Cyanohydrin reacts with carbon dioxide and the aqueous solution of ammonia, and then 5-phenyl-hydantoin and an analogue thereof (hydantoin for short) are generated. hydantoin is successively subjected to steam stripping, alkaline hydrolysis, steam stripping, decolorization, neutralization, crystallization, washing, centrifuging, drying and the like to obtain D, L-phenylglycine and the analogue thereof. Compared with the prior art, the preparation method for D, L-phenylglycine and the analogue thereof can significantly and effectively reduce the pollution, and fewer inorganic salt by-products are generated. Meanwhile, the prepared D, L-phenylglycine and the analogue thereof are high in product yield and high in purity. Counted in benzaldehyde and the analogue thereof, the yield of D, L-phenylglycine and the analogue thereof is larger than or equal to 96%, and the product purity is larger than or equal to 99%. Meanwhile, the process flow is simple and feasible, so that the method is worthy of market popularization and application.

Process for preparation of 2-chlorophenylglycine derivatives and enantiomerically separation

The present invention relates to novel processes and intermediates for the preparation of R(?)-α-2-chlorophenylglycine, S(+)-α-2-chlorophenylglycine, and RS-2-chlorophenylglycine derivatives of formulas I, II and III, respectively. The resulting enantioseparative system was validated in order to evaluate the presence of the enantiomer in pharmaceutical samples. These compounds are found useful as an active ingredient for the pharmaceutical intermediate or as an active ingredient as the tools for delivery of drugs.